197 related articles for article (PubMed ID: 32990511)
1. No Cases of Nephrogenic Systemic Fibrosis after Administration of Gadoxetic Acid.
Starekova J; Bruce RJ; Sadowski EA; Reeder SB
Radiology; 2020 Dec; 297(3):556-562. PubMed ID: 32990511
[TBL] [Abstract][Full Text] [Related]
2. Risk of nephrogenic systemic fibrosis (NSF) in oncology patients receiving gadoxetic acid and updated risk of estimate of NSF in patients receiving gadoxetic acid with moderate and severe renal impairment.
Gauthier ID; Macleod CA; Sathiadoss P; McGrath TA; Nair V; Schieda N
Abdom Radiol (NY); 2022 Mar; 47(3):1196-1201. PubMed ID: 34997298
[TBL] [Abstract][Full Text] [Related]
3. Adverse Events to the Gadolinium-based Contrast Agent Gadoxetic Acid: Systematic Review and Meta-Analysis.
Schieda N; van der Pol CB; Walker D; Tsampalieros AK; Maralani PJ; Woo S; Davenport MS
Radiology; 2020 Dec; 297(3):565-572. PubMed ID: 32452732
[TBL] [Abstract][Full Text] [Related]
4. Incidence of nephrogenic systemic fibrosis at a large university hospital in Sweden.
Alhadad A; Sterner G; Svensson Å; Alhadad H; Leander P
Scand J Urol Nephrol; 2012 Feb; 46(1):48-53. PubMed ID: 22008005
[TBL] [Abstract][Full Text] [Related]
5. Risk of nephrogenic systemic fibrosis in patients with impaired renal function undergoing fixed-dose gadoxetic acid-enhanced magnetic resonance imaging.
Tseng TY; Tseng JH; Huang BS; Lin SY; Chen CB; Fang YW; Lin G; Lai YC
Abdom Radiol (NY); 2021 Aug; 46(8):3995-4001. PubMed ID: 33742216
[TBL] [Abstract][Full Text] [Related]
6. Gadobenate Dimeglumine Administration and Nephrogenic Systemic Fibrosis: Is There a Real Risk in Patients with Impaired Renal Function?
Nandwana SB; Moreno CC; Osipow MT; Sekhar A; Cox KL
Radiology; 2015 Sep; 276(3):741-7. PubMed ID: 25875973
[TBL] [Abstract][Full Text] [Related]
7. Incidence of nephrogenic systemic fibrosis after adoption of restrictive gadolinium-based contrast agent guidelines.
Wang Y; Alkasab TK; Narin O; Nazarian RM; Kaewlai R; Kay J; Abujudeh HH
Radiology; 2011 Jul; 260(1):105-11. PubMed ID: 21586680
[TBL] [Abstract][Full Text] [Related]
8. Nephrogenic systemic fibrosis after gadopentetate dimeglumine exposure: case series of 36 patients.
Abujudeh HH; Kaewlai R; Kagan A; Chibnik LB; Nazarian RM; High WA; Kay J
Radiology; 2009 Oct; 253(1):81-9. PubMed ID: 19709997
[TBL] [Abstract][Full Text] [Related]
9. Low risk for nephrogenic systemic fibrosis in nondialysis patients who have chronic kidney disease and are investigated with gadolinium-enhanced magnetic resonance imaging.
Chrysochou C; Power A; Shurrab AE; Husain S; Moser S; Lay J; Salama AD; Kalra PA
Clin J Am Soc Nephrol; 2010 Mar; 5(3):484-9. PubMed ID: 20093350
[TBL] [Abstract][Full Text] [Related]
10. Retrospective analysis of patients for development of nephrogenic systemic fibrosis following conventional angiography using gadolinium-based contrast agents.
Hoppe H; Spagnuolo S; Froehlich JM; Nievergelt H; Dinkel HP; Gretener S; Thoeny HC
Eur Radiol; 2010 Mar; 20(3):595-603. PubMed ID: 19760239
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of the incidence of nephrogenic systemic fibrosis in patients with moderate renal insufficiency administered gadobenate dimeglumine for MRI.
Bryant BJ; Im K; Broome DR
Clin Radiol; 2009 Jul; 64(7):706-13. PubMed ID: 19520215
[TBL] [Abstract][Full Text] [Related]
12. Nephrogenic systemic fibrosis: risk factors suggested from Japanese published cases.
Tsushima Y; Kanal E; Thomsen HS
Br J Radiol; 2010 Jul; 83(991):590-5. PubMed ID: 20413447
[TBL] [Abstract][Full Text] [Related]
13. Incidence of Nephrogenic Systemic Fibrosis Using Gadobenate Dimeglumine in 1423 Patients With Renal Insufficiency Compared With Gadodiamide.
Bruce R; Wentland AL; Haemel AK; Garrett RW; Sadowski DR; Djamali A; Sadowski EA
Invest Radiol; 2016 Nov; 51(11):701-705. PubMed ID: 26885631
[TBL] [Abstract][Full Text] [Related]
14. Gadolinium-based contrast exposure, nephrogenic systemic fibrosis, and gadolinium detection in tissue.
Wiginton CD; Kelly B; Oto A; Jesse M; Aristimuno P; Ernst R; Chaljub G
AJR Am J Roentgenol; 2008 Apr; 190(4):1060-8. PubMed ID: 18356456
[TBL] [Abstract][Full Text] [Related]
15. Nephrogenic systemic fibrosis: incidence, associations, and effect of risk factor assessment--report of 33 cases.
Perez-Rodriguez J; Lai S; Ehst BD; Fine DM; Bluemke DA
Radiology; 2009 Feb; 250(2):371-7. PubMed ID: 19188312
[TBL] [Abstract][Full Text] [Related]
16. Nephrogenic systemic fibrosis: risk factors and incidence estimation.
Sadowski EA; Bennett LK; Chan MR; Wentland AL; Garrett AL; Garrett RW; Djamali A
Radiology; 2007 Apr; 243(1):148-57. PubMed ID: 17267695
[TBL] [Abstract][Full Text] [Related]
17. Prospective Cohort Study of Nephrogenic Systemic Fibrosis in Patients With Stage 3-5 Chronic Kidney Disease Undergoing MRI With Injected Gadobenate Dimeglumine or Gadoteridol.
Soulez G; Bloomgarden DC; Rofsky NM; Smith MP; Abujudeh HH; Morgan DE; Lichtenstein RJ; Schiebler ML; Wippold FJ; Russo C; Kuhn MJ; Mennitt KW; Maki JH; Stolpen A; Liou J; Semelka RC; Kirchin MA; Shen N; Pirovano G; Spinazzi A
AJR Am J Roentgenol; 2015 Sep; 205(3):469-78. PubMed ID: 26295633
[TBL] [Abstract][Full Text] [Related]
18. A Systematic Review of 639 Patients with Biopsy-confirmed Nephrogenic Systemic Fibrosis.
Attari H; Cao Y; Elmholdt TR; Zhao Y; Prince MR
Radiology; 2019 Aug; 292(2):376-386. PubMed ID: 31264946
[TBL] [Abstract][Full Text] [Related]
19. Half-dose gadoxetic acid-enhanced liver magnetic resonance imaging in patients at risk for nephrogenic systemic fibrosis.
Song KD; Kim SH; Lee J; Kang KA; Kim J; Yoo H
Eur J Radiol; 2015 Mar; 84(3):378-383. PubMed ID: 25591579
[TBL] [Abstract][Full Text] [Related]
20. Absence of potential gadolinium toxicity symptoms following 22,897 gadoteric acid (Dotarem®) examinations, including 3,209 performed on renally insufficient individuals.
Young LK; Matthew SZ; Houston JG
Eur Radiol; 2019 Apr; 29(4):1922-1930. PubMed ID: 30276674
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
